A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly...

Area of Science:

• Biomarkers and Diagnostics
• Cancer Research
• Nanotechnology in Medicine

Background:

• Pancreatic ductal adenocarcinoma (PDAC) detection faces challenges due to low incidence and limitations of current screening methods, often resulting in high false-positive rates.
• Existing diagnostic approaches for PDAC are frequently invasive, costly, and complex, necessitating improvements in specificity and sensitivity.
• The need for advanced, noninvasive, and accurate screening tools for PDAC is critical for early detection and improved patient outcomes.

Purpose of the Study:

• To develop and validate EV-FRET, a novel fluorescence resonance energy transfer (FRET)-based assay for rapid, specific, and noninvasive detection of pancreatic ductal adenocarcinoma (PDAC).
• To leverage extracellular vesicles (EVs) and their unique molecular composition for a highly sensitive and specific PDAC diagnostic tool.
• To establish a low-cost, single-step assay that surpasses the diagnostic accuracy of current clinical standards like CA19-9.

Main Methods:

• Development of the EV-FRET assay utilizing fluorescence resonance energy transfer (FRET) to detect specific biomarkers on extracellular vesicles (EVs).
• Targeting of β-sheet-rich tumorous proteins (pan-cancer) and N-acetyl-d-galactosamine (pancreas-specific) on EVs using modified fluorophores (thioflavin T and Dolichos biflorus agglutinin).
• Assay validation through diagnostic accuracy assessment, comparing EV-FRET performance against the CA19-9 biomarker in PDAC detection.

Main Results:

• EV-FRET demonstrated superior diagnostic accuracy for PDAC detection with an area under the curve (AUC) of 0.95, significantly outperforming CA19-9 (AUC=0.72).
• The assay exhibited high reproducibility (CV <4%), rapid processing time (<15 min), and low estimated reagent costs (<$15/test).
• EV-FRET operates as a simple, single-step method without requiring EV enrichment or isolation, enhancing its practicality.

Conclusions:

• EV-FRET represents a transformative, highly specific, and scalable diagnostic solution for pancreatic cancer, integrating organ-specific and tumor-specific biomarkers.
• The assay's noninvasive nature, speed, low cost, and superior accuracy position it as a significant advancement over current PDAC detection methods.
• EV-FRET has the potential to substantially improve patient outcomes through more precise and accessible early detection of pancreatic ductal adenocarcinoma.